We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.7B
AUM Growth
-$152M
Cap. Flow
+$293M
Cap. Flow %
3.03%
Top 10 Hldgs %
29.73%
Holding
234
New
14
Increased
60
Reduced
64
Closed
43

Top Buys

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$74.9M
2
ABT icon
Abbott
ABT
+$45.9M
3
MOH icon
Molina Healthcare
MOH
+$43.5M
4
DHR icon
Danaher
DHR
+$42M
5
MDT icon
Medtronic
MDT
+$38M

Top Sells

Rank Stock Value
1
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$63.1M
2
BAX icon
Baxter International
BAX
+$38.1M
3
CNC icon
Centene
CNC
+$36.2M
4
HOLX
Hologic
HOLX
+$21.4M
5
DXCM icon
DexCom
DXCM
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Technology 0.8%
3 Industrials 0.75%
4 Communication Services 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
101
Avantor
AVTR
$7.56B
$21.6M 0.22%
512,216
– –
NVRO
102
DELISTED
NEVRO CORP.
NVRO
$19.3M 0.2%
237,841
+22,885
+11% +$2.29M
BDTX icon
103
Black Diamond Therapeutics
BDTX
$103M
$18.5M 0.19%
3,463,000
– –
QTRX icon
104
Quanterix
QTRX
$182M
$16.9M 0.17%
397,464
-196,355
-33% -$9.17M
NEO icon
105
NeoGenomics
NEO
$1.9B
$16M 0.17%
469,695
-91,988
-16% -$3.6M
ONEM
106
DELISTED
1Life Healthcare
ONEM
$14.7M 0.15%
836,190
– –
WVE icon
107
Wave Life Sciences
WVE
$1.12B
$14.5M 0.15%
4,602,858
+2,000,000
+77% +$8.3M
PRVA icon
108
Privia Health
PRVA
$3.39B
$13.6M 0.14%
525,000
– –
AMGN icon
109
Amgen
AMGN
$198B
$13.1M 0.13%
58,150
+24,200
+71% +$5.11M
AMWL icon
110
American Well
AMWL
$221M
$12.9M 0.13%
106,392
– –
GILD icon
111
Gilead Sciences
GILD
$167B
$11.4M 0.12%
157,000
– –
TMDX icon
112
Transmedics
TMDX
$2.56B
$11.1M 0.11%
581,029
– –
XRAY icon
113
Dentsply Sirona
XRAY
$2.81B
$8.88M 0.09%
159,129
– –
ZLAB icon
114
Zai Lab
ZLAB
$2.28B
$7.96M 0.08%
126,600
+1,600
+1% +$136K
SGEN
115
DELISTED
Seagen Inc. Common Stock
SGEN
$7.11M 0.07%
46,000
-7,400
-14% -$1.24M
CELL
116
DELISTED
PhenomeX Inc. Common Stock
CELL
$7M 0.07%
385,014
– –
NBP
117
NovaBridge Biosciences American Depositary Shares
NBP
$206M
$6.87M 0.07%
144,957
-18,000
-11% -$1.08M
PFE icon
118
Pfizer
PFE
$143B
$6.67M 0.07%
113,000
+13,400
+13% +$664K
QTTB icon
119
Q32 Bio
QTTB
$346M
$6.32M 0.07%
96,507
– –
BMRN icon
120
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.31M 0.07%
71,400
+19,700
+38% +$1.63M
ONC
121
BeOne Medicines Ltd
ONC
$32.4B
$6.23M 0.06%
23,000
– –
LUNG icon
122
Pulmonx
LUNG
$59.1M
$5.66M 0.06%
176,510
– –
OSCR icon
123
Oscar Health
OSCR
$8.77B
$5.34M 0.06%
679,952
– –
SGHT icon
124
Sight Sciences
SGHT
$274M
$5.27M 0.05%
300,000
– –
BHVN
125
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.24M 0.05%
38,007
+20,507
+117% +$2.61M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2021 Portfolio in Review

As of Q4 2021, Bellevue Group held 234 positions worth $9.7B, down 1.5% from $9.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group deployed $293M of net new capital in Q4 2021, opening 14 new positions and adding to 60 existing holdings. Its largest new stake was AstraZeneca: 29,500 shares worth $3.44M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Baxter International, an estimated $38.1M trimmed.

  • Bellevue Group's largest Q4 2021 buy was AstraZeneca: 29,500 shares worth $3.44M.
  • Bellevue Group added most to CareDx in Q4 2021, an estimated $74.9M increase.
  • Bellevue Group's biggest Q4 2021 reduction was Baxter International, cutting an estimated $38.1M.
  • Bellevue Group fully exited HILL-ROM HOLDINGS, INC. in Q4 2021, selling an estimated $63.1M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.7B portfolio in Q4 2021.
  • Bellevue Group opened 14 new positions and closed 43 in Q4 2021.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $9.7B.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.